A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis

European Journal of Clinical Investigation

Volumn 37, Issue 4, 2007, Pages 249-256

  Park, S H ^a   Kim, J R ^a   Park, J E ^b   Cho, K H ^a  

^a Yeungnam University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Apolipoprotein A I; Apolipoprotein A II; High density lipoproteins; Hypolipidaemia; Obesity

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A2; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CASE REPORT; CENTRIFUGATION; CHOLESTEROL BLOOD LEVEL; ELECTRON MICROSCOPY; ELECTROPHORESIS; HUMAN; HYPERLIPIDEMIA; IMMUNODETECTION; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN ISOLATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; ATHEROSCLEROSIS; BIOLOGICAL ASSAY; CHOLESTEROL; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; MALE; MIDDLE AGED; OBESITY;

EID: 33947309596     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01768.x     Document Type: Article

References (26)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;62:707-14.
2. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
3. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
4. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G et al. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 2004;15:645-9.
5. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 2001;42:1727-39.
6. Chiesa G, Parolini C, Canavesi M, Colombo N, Sirtori CR et al. Human apoA-I and A-II in cell cholesterol efflux studies with transgenic mice. Arterioscler Thromb Vasc Biol 1998;18:1417-23.
7. Julve J, Escola-Gil JC, Ribas V, Gonzalez-Sastre F, Ordonez-Llanos J et al. Mechanisms of HDL deficiency in mice overexpressing human apoA-II. J Lipid Res 2002;43:1734-42.
8. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoproteins A-II. Science 1993;261:469-72.
9. Ribas V, Sanchez-Quesada JL, Anton R, Camacho M, Julve J et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 2004;95:789-97.
10. Carr MC, Brunzell JD. Abdominal obesity and dyslipidaemia in the metabolic syndrome. Importance of type 2 diabetes and familial combined hyperlipidaemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89:2601-7.
11. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions the atherosclerosis risk in communities (ARIC) study. Circulation 2001;104:1108-13.
12. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206-10.
13. Han JM, Jeong TS, Lee WS, Choi I, Cho KH. Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J Lipid Res 2005;46:589-96.
14. Cho KH, Lee JY, Choi MS, Cho JM, Lim JS, Park YB. A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim Biophys Acta 1998;1391:133-44.
15. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968;9:693-700.
16. Cho KH, Durbin DM, Jonas A. Role of individual amino acids of apolipoprotein A-I in the activation of lecithin. cholesterol acyltranferase and in HDL rearrangements. J Lipid Res 2001;42:379-89.
17. Kosek AB, Durbin D, Jonas A. Binding affinity and reactivity of lecithin cholesterol acyltrasferase with native lipoproteins. Biochem Biophys Res Commun 1999;258:548-51.
18. Speijer H, Groener JEM, van Ramshorst E, van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991;90:159-68.
19. Bu X, Warden CH, Xia YR, De Meester C, Puppione DL et al. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein Loci. Hum Genet 1994;93:639-48.
20. Brewer HB, Lux SE, Ronan R, Jhon KM. Amino acid sequence of human apoLp GlnII (apoA-II), an apolipoproteins isolated from the high density lipoprotein. Proc Natl Acad Sci USA 1972;69:1304-8.
21. Castro G, Nihoul LP, Dengremont C, de Geitere C, Delfly B et al. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry 1997;36:2243-9.
22. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J et al. Functional Lecithin: cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem 1996;271:6720-8.
23. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005;112:879-84.
24. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997;38:191-205.
25. Lagrost L, Dengremont C, Athias A, de Geitere C, Fruchart JC et al. Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. Particles containing various proportions of apolipoprotein A-I and A-II. J Biol Chem 1995;270:13004-9.
26. Fournier N, Cogny A, Atger V, Pastier D, Goudouneche D et al. Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells. Arterioscler Thromb Vasc Biol 2002;22:638-43.